Immune checkpoint inhibitors and timing of administration

Affiliations

¹ Medical Oncology, University Hospital Waterford, Waterford X91 ER8E, Ireland. Electronic address: timothyn.obrien@hse.ie.
² Pharmacy Department, Midland Regional Hospital Tullamore, Tullamore, Ireland.

Comment

Timothy O'Brien et al. Lancet Oncol. 2022 Feb.

. 2022 Feb;23(2):e55.

doi: 10.1016/S1470-2045(21)00704-X.

¹ Medical Oncology, University Hospital Waterford, Waterford X91 ER8E, Ireland. Electronic address: timothyn.obrien@hse.ie.
² Pharmacy Department, Midland Regional Hospital Tullamore, Tullamore, Ireland.

No abstract available

Conflict of interest statement

We declare no competing interests.

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC, Kleber T, Brammer B, Xu KM, Switchenko JM, Janopaul-Naylor JR, Zhong J, Yushak ML, Harvey RD, Paulos CM, Lawson DH, Khan MK, Kudchadkar RR, Buchwald ZS. Qian DC, et al. Lancet Oncol. 2021 Dec;22(12):1777-1786. doi: 10.1016/S1470-2045(21)00546-5. Epub 2021 Nov 12. Lancet Oncol. 2021. PMID: 34780711 Clinical Trial.
Immune checkpoint inhibitors and timing of administration.
Dizman N, Velazquez AI, Duma N. Dizman N, et al. Lancet Oncol. 2022 Feb;23(2):e56. doi: 10.1016/S1470-2045(22)00009-2. Lancet Oncol. 2022. PMID: 35114125 No abstract available.
Immune checkpoint inhibitors and timing of administration - Authors' reply.
Qian DC, Buchwald ZS. Qian DC, et al. Lancet Oncol. 2022 Feb;23(2):e57. doi: 10.1016/S1470-2045(22)00023-7. Lancet Oncol. 2022. PMID: 35114126 No abstract available.